Figure 8

Effects of LCI699 on plasma renin activity (PRA) (human study, multiple-dose phase). Percentage change in PRA from time-matched baseline during once-daily treatment with LCI699 (0.5, 1 or 3 mg), eplerenone (100 mg) or placebo for 14 days in healthy human volunteers, and at 24, 48 and 72 h after the final dose. Values are mean ± SEM. Number of evaluable subjects for LCI699 0.5, 1, 3 mg, eplerenone and placebo were n = 12, 12, 12, 10 and 9 respectively. *P < 0.05, ^† P < 0.01, ^‡ P < 0.001 vs placebo.